Literature DB >> 25388609

Hypochondriasis: considerations for ICD-11.

Odile A van den Heuvel1, David Veale2, Dan J Stein3.   

Abstract

The World Health Organization (WHO) is currently revisiting the ICD. In the 10th version of the ICD, approved in 1990, hypochondriacal symptoms are described in the context of both the primary condition hypochondriacal disorder and as secondary symptoms within a range of other mental disorders. Expansion of the research base since 1990 makes a critical evaluation and revision of both the definition and classification of hypochondriacal disorder timely. This article addresses the considerations reviewed by members of the WHO ICD-11 Working Group on the Classification of Obsessive-Compulsive and Related Disorders in their proposal for the description and classification of hypochondriasis. The proposed revision emphasizes the phenomenological overlap with both anxiety disorders (e.g., fear, hypervigilance to bodily symptoms, and avoidance) and obsessive-compulsive and related disorders (e.g., preoccupation and repetitive behaviors) and the distinction from the somatoform disorders (presence of somatic symptom is not a critical characteristic). This revision aims to improve clinical utility by enabling better recognition and treatment of patients with hypochondriasis within the broad range of global health care settings.

Entities:  

Mesh:

Year:  2014        PMID: 25388609     DOI: 10.1590/1516-4446-2013-1218

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  8 in total

1.  Health anxiety symptoms in children and adolescents diagnosed with OCD.

Authors:  Anna Villadsen; Mette V Thorgaard; Katja A Hybel; Jens Søndergaard Jensen; Per H Thomsen; Charlotte U Rask
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-06-29       Impact factor: 4.785

2.  An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5.

Authors:  Michael B First; Wolfgang Gaebel; Mario Maj; Dan J Stein; Cary S Kogan; John B Saunders; Vladimir B Poznyak; Oye Gureje; Roberto Lewis-Fernández; Andreas Maercker; Chris R Brewin; Marylene Cloitre; Angelica Claudino; Kathleen M Pike; Gillian Baird; David Skuse; Richard B Krueger; Peer Briken; Jeffrey D Burke; John E Lochman; Spencer C Evans; Douglas W Woods; Geoffrey M Reed
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

Review 3.  New challenges in facing Cyberchondria during the COVID-19 pandemic.

Authors:  Matteo Vismara; Alberto Varinelli; Luca Pellegrini; Arun Enara; Naomi A Fineberg
Journal:  Curr Opin Behav Sci       Date:  2022-05-13

4.  Using Fear and Anxiety Related to COVID-19 to Predict Cyberchondria: Cross-sectional Survey Study.

Authors:  Xue Wu; Nabi Nazari; Mark D Griffiths
Journal:  J Med Internet Res       Date:  2021-06-09       Impact factor: 7.076

5.  Use of Web-Based Health Services in Individuals With and Without Symptoms of Hypochondria: Survey Study.

Authors:  Christiane Eichenberg; Markus Schott
Journal:  J Med Internet Res       Date:  2019-06-10       Impact factor: 5.428

6.  The mediating effect of the cyberchondria and anxiety sensitivity in the association between problematic internet use, metacognition beliefs, and fear of COVID-19 among Iranian online population.

Authors:  Seyed Ghasem Seyed Hashemi; Shalaleh Hosseinnezhad; Solmaz Dini; Mark D Griffiths; Chung-Ying Lin; Amir H Pakpour
Journal:  Heliyon       Date:  2020-10-10

7.  Gray Matter Volume and Functional Connectivity in Hypochondriasis: A Magnetic Resonance Imaging and Support Vector Machine Analysis.

Authors:  Zhe Shen; Liang Yu; Zhiyong Zhao; Kangyu Jin; Fen Pan; Shaohua Hu; Shangda Li; Yi Xu; Dongrong Xu; Manli Huang
Journal:  Front Hum Neurosci       Date:  2020-12-02       Impact factor: 3.169

8.  The Portrait of Cyberchondria-A Cross-Sectional Online Study on Factors Related to Health Anxiety and Cyberchondria in Polish Population during SARS-CoV-2 Pandemic.

Authors:  Marta Ciułkowicz; Błażej Misiak; Dorota Szcześniak; Jolanta Grzebieluch; Julian Maciaszek; Joanna Rymaszewska
Journal:  Int J Environ Res Public Health       Date:  2022-04-05       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.